Cardiovascular disease: several compounds have cardiovascular outcome trials. SELECT was in people without diabetes; SUSTAIN 6 was in high-risk diabetes. Absolute benefit is largest in high-risk people. It cost nothing to check and would have cost something not to.
Posting this under the heading it deserves: Gallbladder disease risk with rapid weight loss Everything below is what sits behind that.
Gallbladder disease risk — I have the observation and I do not trust my interpretation of it, so I am posting the observation and holding the interpretation back.
Numbers, method and the conditions under which they were collected are below. Interpret them however they warrant.
Two people in this thread mean different things by gallbladder disease risk and are disagreeing about the definition while believing they are disagreeing about the facts. Worth pausing to define it.
On post #2 — agreed on the reasoning, with one qualification.
Nothing here is medical advice and clinicians posting in this subcategory say so on their own account rather than because a rule requires it.
The short version is the first sentence; the rest is why.
Post #4 answers the question as asked. The question underneath it is different.
Practical answer on gallbladder disease risk, since the theoretical one is upthread: do the simplest check first, write down the result, and only then decide whether the complicated explanation is needed. It usually is not.
Chronic kidney disease: compounds in this class have renal benefit in people with kidney disease. The benefit appears to be additive to other renal-protective agents, not a replacement for them.
The version of gallbladder disease risk that circulates here is a simplification of a simplification. It is not wrong, but it has lost the conditions under which it holds, and those conditions are where the interesting cases live.
The practical value of this subcategory is helping somebody frame the question they take to an appointment, and that is worth being explicit about.
Reading it back, the second half matters more than the first.
Cardiovascular disease: several compounds have cardiovascular outcome trials. SELECT was in people without diabetes; SUSTAIN 6 was in high-risk diabetes. Absolute benefit is largest in high-risk people.
It cost nothing to check and would have cost something not to.
Everything in post #6 holds. The case it does not cover is the one I have.
Reading back through the gallbladder disease risk threads from last year, the same three questions come up every time and only one of them has ever been answered properly. That seems like a documentation gap rather than a knowledge gap.
I had written a reply contradicting post #9 and deleted it. Here is what survived.
I read the earlier replies on gallbladder disease risk twice before writing this, because I had assumed the opposite and wanted to be sure I was disagreeing with what was said rather than what I expected.
This is the answer, and the reason it is the answer is the more useful part.
Picking up post #12: that is the part I would want checked first.
Multiple comorbidities: a person with diabetes, kidney disease, and cardiovascular disease is outside the studied populations in most trials. Extrapolating to that person requires reasoning from the individual component trials and mechanisms.
Coming back to post #14, because the follow-up matters more than the original answer.
Bariatric surgery history: altered anatomy after surgery affects absorption. That matters for oral medications and for reconstituted solutions. Discussing specific medications and doses with a clinician familiar with bariatric surgery is prudent.
Where the gallbladder disease risk discussion usually stalls is that nobody wants to say "I do not know" and everyone is willing to say "it varies". Those are the same sentence with different clothes on.
Where the honest answer is "nobody knows", giving it plainly is more useful than a confident synthesis of mechanism and anecdote.
That much is documented. The rest is how I have interpreted it.
Obstructive sleep apnoea: SURMOUNT-OSA used an objective endpoint, the apnoea-hypopnoea index. Reduction was substantial. Whether the benefit is weight loss or a direct drug effect is not resolved by the trial.
Where I would look next, rather than where I would stop.
Building on post #17 rather than restating it.
A condition that affects nutrition or absorption changes the calculus around a treatment that reduces intake, and that interaction is mostly unstudied.
The bit of gallbladder disease risk that nobody enjoys is that the answer changes depending on what you are trying to decide with it. Say what the decision is and the thread will converge.
Fine by me. I had wanted a stronger conclusion and there is not one available.
Worth separating two things that post #20 runs together.
Something worth flagging about gallbladder disease risk: the strongest-sounding claims in this thread are the ones with no source attached, which is the usual pattern and not a coincidence.
Post #22 answers the question as asked. The question underneath it is different.
Where two conditions pull in opposite directions, that is a clinical judgement rather than a lookup, and it is the kind of question a forum answers worst.
Obstructive sleep apnoea: SURMOUNT-OSA used an objective endpoint, the apnoea-hypopnoea index. Reduction was substantial. Whether the benefit is weight loss or a direct drug effect is not resolved by the trial.
Scoping that to what I have actually seen rather than what I have read.
Chronic kidney disease: compounds in this class have renal benefit in people with kidney disease. The benefit appears to be additive to other renal-protective agents, not a replacement for them.
Second-hand, so weight it accordingly.
Narrowing post #26, because the general version has more than one answer.
Gallbladder disease risk came up in a thread eighteen months ago and was answered well. I cannot find it, which is itself the problem, so here is the reconstruction.
Everything in post #28 holds. The case it does not cover is the one I have.
A note on how gallbladder disease risk gets discussed rather than on gallbladder disease risk itself: the confident posts get the replies and the careful ones get ignored, and the careful ones have been right more often.